4basebio UK Societas Further re Conversion to UK PLC
July 23 2021 - 9:39AM
UK Regulatory
TIDM4BB
23 July 2021
4basebio UK Societas
("4basebio" or the "Company")
Further re: Conversion to UK PLC
Further to the announcement of 21 July 2021, 4basebio UK Societas (AIM: 4BB),
the specialist life sciences group focused on exploiting intellectual property
in the field of gene therapies and vaccines, announces that, as a result of the
Company's conversion to a UK plc, the following changes will occur:
1. the Company's name will change from 4basebio UK Societas to its new
registered name, 4basebio PLC;
2. the Company's current ISIN GB00BLD8ZL39 will be replaced by the new ISIN
GB00BMCLYF79; and
3. the Company's current SEDOL BLD8ZL3 will be replaced with the new SEDOL
BMCLYF7.
The record date for the changes will be 28 July 2021 and the changes will take
effect from 07:00 on 29 July 2021.
The Company's existing TIDM of 4BB remains unchanged.
For further enquiries, please contact:
4basebio UK Societas +44 (0)12 2396 7943
Heikki Lanckriet, CEO
Cairn Financial Advisers LLP (Nominated +44 (0)20 7213 0880
Adviser)
Jo Turner / Sandy Jamieson
finnCap Ltd (Broker) +44 (0)20 7220 0500
Geoff Nash/Richard Chambers/Charlotte
Sutcliffe
Walbrook PR +44 (0)20 7933 8780 or
4basebio@walbrookpr.com
Anna Dunphy / Paul McManus Mob: +44 (0)7876 741 001 / +44 (0)7980 541
893
Notes to Editors
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic
DNA for gene therapies and DNA vaccines and providing solutions for effective
and safe delivery of these DNA based products to patients. It is the intention
of the Company to become a market leader in the manufacture and supply of high
purity, synthetic DNA for research, therapeutic and pharmacological use. The
immediate objectives of 4bb are to validate and scale its DNA synthesis and
advance its collaborations to facilitate the functional validation of its DNA
based products and gene delivery solutions.
The Company divested from 4basebio AG ("4bb AG"), a German company listed on
the Prime Standard segment of the Frankfurt Stock Exchange, following the
disposal by 4bb AG (then named Expedeon AG) of its proteomics and immunology
business to AIM-quoted Abcam plc in January 2020 for ?120million. Following the
disposal, 4bb AG retained its genomics business which owned and licensed
certain intellectual property including its proprietary, patent-protected
technology, TruePrimeT. This is the foundation for building the Company's
synthetic DNA manufacturing business which 4bb AG transferred to the Company
along with funding to continue the Company's development and investment.
END
(END) Dow Jones Newswires
July 23, 2021 10:39 ET (14:39 GMT)
4basebio (LSE:4BB)
Historical Stock Chart
From Apr 2024 to May 2024
4basebio (LSE:4BB)
Historical Stock Chart
From May 2023 to May 2024